# GenSci145 as Monotherapy or in Combination Therapy, in Participants With PIK3CA-mutated, Locally Advanced or Metastatic Solid Tumors.

> **NCT07407504** · PHASE1 · NOT_YET_RECRUITING · sponsor: **Changchun GeneScience Pharmaceutical Co., Ltd.** · enrollment: 186 (estimated)

## Conditions studied

- Locally Advanced or Metastatic Solid Tumors With PIK3CA-mutated

## Interventions

- **DRUG:** GenSci145 tablets

## Key facts

- **NCT ID:** NCT07407504
- **Lead sponsor:** Changchun GeneScience Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-03-14
- **Primary completion:** 2028-11-08
- **Final completion:** 2029-02-21
- **Target enrollment:** 186 (ESTIMATED)
- **Last updated:** 2026-02-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07407504

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07407504, "GenSci145 as Monotherapy or in Combination Therapy, in Participants With PIK3CA-mutated, Locally Advanced or Metastatic Solid Tumors.". Retrieved via AI Analytics 2026-07-15 from https://api.ai-analytics.org/clinical/NCT07407504. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*